Phase 3 Readout
BMY: Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Saf
October 5, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 5, 2026
- Company
- BRISTOL MYERS SQUIBB CO (BMY)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Saf
- Indication
- Psychosis Associated With Alzheimer's Disease
Other upcoming events for BMY
Phase 2 StartPhase 2 Start: A Phase 2, Multicenter, Open-Label Study of Zolacabtagene Autoleucel (BMS-986353), CD19-Targeted NEX
Phase 2 StartPhase 2 Start: A Phase 1/2a, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetic
Phase 1 StartPhase 1 Start: A Phase 1 Study to Evaluate the Mass Balance, Metabolism, Excretion, and Pharmacokinetics of [14C]Na
Phase 2 StartPhase 2 Start: A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Monotherapy, Multicenter St
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of